​

Palvella Therapeutics (PVLA) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

PVLA Stock Forecast

Palvella Therapeutics (PVLA) stock forecast, based on 9 Wall Street analysts, predicts a 12-month average price target of $185.92, with a high of $210.00 and a low of $143.00. This represents a 78.80% increase from the last price of $103.98.

PVLA Stock Rating

Palvella Therapeutics stock's rating consensus is Buy, based on 9 Wall Street analysts. The breakdown includes 1 Strong Buy (11.11%), 8 Buy (88.89%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 9 0 8 1 Strong Sell Sell Hold Buy Strong Buy

PVLA Price Target Upside V Benchmarks

TypeNameUpside
StockPalvella Therapeutics78.80%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts11626
Avg Price Target$205.00$183.19$142.58
Last Closing Price$103.98$103.98$103.98
Upside/Downside97.15%76.18%37.12%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 26-14---14
Dec, 25-12---12
Nov, 25310---13
Oct, 25310---13
Sep, 2539---12
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 07, 2026Mizuho Securities$205.00$90.43126.69%97.15%
Dec 16, 2025Whitney IjemCanaccord Genuity$204.00$88.42130.72%96.19%
Dec 16, 2025Ryan DeschnerRaymond James$193.00$91.51110.91%85.61%
Dec 15, 2025Chardan Capital$174.00$88.4296.79%67.34%
Dec 15, 2025Jeff MukherjeeBTIG$192.00$88.42117.15%84.65%
Dec 15, 2025Truist Financial$190.00$88.89113.75%82.73%
Dec 15, 2025Catherine NovackUBS$143.00$88.4261.73%37.53%
Dec 15, 2025H.C. Wainwright$200.00$90.63120.68%92.34%
Dec 15, 2025Cantor Fitzgerald$210.00$88.72136.70%101.96%
Dec 15, 2025Oppenheimer$200.00$87.43128.75%92.34%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 16, 2025Cowen & Co.BuyBuyhold
Dec 16, 2025Raymond JamesStrong BuyStrong Buyhold
Dec 15, 2025BTIGBuyBuyhold
Dec 15, 2025UBSBuyBuyhold
Dec 15, 2025Cantor FitzgeraldOverweightOverweighthold
Dec 15, 2025OppenheimerOutperformOutperformhold
Dec 11, 2025H.C. WainwrightBuyBuyhold
Dec 05, 2025BTIGBuyinitialise
Dec 04, 2025Craig-HallumBuyinitialise
Nov 11, 2025OppenheimerOutperformOutperformhold

Financial Forecast

EPS Forecast

$-15 $-12 $-9 $-6 $-3 $0 Dec 24 Dec 25 Dec 26 Dec 27
Dec 24Dec 25Dec 26Dec 27
Reported$-7.83---
Avg Forecast$-3.70$-2.77$-5.41$-2.81
High Forecast$-3.02$-1.60$-1.48$-1.37
Low Forecast$-4.37$-3.93$-12.67$-4.16
Surprise %111.62%---

Revenue Forecast

Dec 24 Dec 25 Dec 26 Dec 27
Dec 24Dec 25Dec 26Dec 27
Reported----
Avg Forecast$50.00K--$5.62M
High Forecast$50.00K--$5.62M
Low Forecast$50.00K--$5.62M
Surprise %----

Net Income Forecast

$-30M $-24M $-18M $-12M $-6M $0 Dec 24 Dec 25 Dec 26 Dec 27
Dec 24Dec 25Dec 26Dec 27
Reported$-17.43M---
Avg Forecast$-8.22M$-6.15M$-15.75M$-6.15M
High Forecast$-6.72M$-3.56M$-3.29M$-3.05M
Low Forecast$-9.73M$-8.75M$-28.20M$-9.26M
Surprise %111.97%---

PVLA Forecast FAQ

Is Palvella Therapeutics stock a buy?

Palvella Therapeutics stock has a consensus rating of Buy, based on 9 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 8 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Palvella Therapeutics is a favorable investment for most analysts.

What is Palvella Therapeutics's price target?

Palvella Therapeutics's price target, set by 9 Wall Street analysts, averages $185.92 over the next 12 months. The price target range spans from $143 at the low end to $210 at the high end, suggesting a potential 78.80% change from the previous closing price of $103.98.

How does Palvella Therapeutics stock forecast compare to its benchmarks?

Palvella Therapeutics's stock forecast shows a 78.80% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Palvella Therapeutics over the past three months?

  • January 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2025: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 23.08% Strong Buy, 76.92% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Palvella Therapeutics’s EPS forecast?

Palvella Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.77, marking a -64.62% decrease from the reported $-7.83 in 2024. Estimates for the following years are $-5.41 in 2026, and $-2.81 in 2027.

What is Palvella Therapeutics’s revenue forecast?

Palvella Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $0, and $5.62M for 2027.

What is Palvella Therapeutics’s net income forecast?

Palvella Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-6.155M, representing a -64.70% decrease from the reported $-17.434M in 2024. Projections indicate $-15.748M in 2026, and $-6.155M in 2027.